Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Other Operating Expenses (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Other Operating Expenses for 15 consecutive years, with $6.5 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses rose 5.34% to $6.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $32.4 million through Dec 2025, up 27.5% year-over-year, with the annual reading at $32.9 million for FY2025, 27.5% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $6.5 million at Aytu Biopharma, up from $5.8 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $14.4 million in Q4 2022, with the low at -$53.1 million in Q1 2022.
  • Average Other Operating Expenses over 5 years is -$383736.8, with a median of $6.3 million recorded in 2024.
  • The sharpest move saw Other Operating Expenses crashed 422.75% in 2021, then soared 224.98% in 2022.
  • Over 5 years, Other Operating Expenses stood at -$11.5 million in 2021, then skyrocketed by 224.98% to $14.4 million in 2022, then tumbled by 57.49% to $6.1 million in 2023, then increased by 0.93% to $6.2 million in 2024, then grew by 5.34% to $6.5 million in 2025.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $6.5 million, $5.8 million, and $14.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.